19KA Stock Overview
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CorMedix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.40 |
| 52 Week High | US$12.70 |
| 52 Week Low | US$2.66 |
| Beta | 1.58 |
| 11 Month Change | -17.54% |
| 3 Month Change | 72.48% |
| 1 Year Change | 181.44% |
| 33 Year Change | 111.71% |
| 5 Year Change | 70.91% |
| Change since IPO | -34.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 19KA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.6% | 1.4% | 0.8% |
| 1Y | 181.4% | -18.4% | 9.1% |
Return vs Industry: 19KA exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 19KA exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 19KA volatility | |
|---|---|
| 19KA Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 19KA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 19KA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 83 | Joe Todisco | www.cormedix.com |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. Fundamentals Summary
| 19KA fundamental statistics | |
|---|---|
| Market cap | €575.82m |
| Earnings (TTM) | -€43.97m |
| Revenue (TTM) | €11.68m |
49.2x
P/S Ratio-13.1x
P/E RatioIs 19KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 19KA income statement (TTM) | |
|---|---|
| Revenue | US$12.26m |
| Cost of Revenue | US$2.01m |
| Gross Profit | US$10.25m |
| Other Expenses | US$56.40m |
| Earnings | -US$46.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 83.57% |
| Net Profit Margin | -376.35% |
| Debt/Equity Ratio | 0% |
How did 19KA perform over the long term?
See historical performance and comparison